Understand the source comparison
Best Peptides for Sexual Function Research: Mechanism Comparison
PT-141 (bremelanotide) Melanocortin receptor agonist MC4R (selective) 2–3 hours SC Central arousal independent of vascular function Strongest clinical evidence for arousal endpoints in both sexes. FDA-approved for FSAD Melanotan II MC1R, MC3R, MC4R, MC5R (non-
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- PT-141 (bremelanotide)
- Melanocortin receptor agonist
- MC4R (selective)
- 2–3 hours SC
- Central arousal independent of vascular function
- Strongest clinical evidence for arousal endpoints in both sexes. FDA-approved for FSAD
- Melanotan II
- MC1R, MC3R, MC4R, MC5R (non-selective)
- Animal models where pigmentation tracking is needed
- Broader receptor activity than PT-141 but pigmentation side effects limit human use
- Kisspeptin-10
- GnRH secretagogue
- GPR54 (KISS1R)
- 27 min IV, 45 min SC
- Upstream HPG axis modulation and gonadotropin studies
- Only peptide that works through endogenous hormonal pathways. Requires intact HPG function
- Oxytocin
- Neuropeptide hormone
- OXTR (brain and peripheral)
- 3–5 min IV, intranasal variable
- Orgasmic response and social bonding research
- Moderate effect size with high variability. Best for neurobehavioral endpoints
- DHEA
- Androgen precursor (not a peptide)
- Converts to testosterone/estradiol
- 15–30 hours oral
- Baseline androgen augmentation in hypogonadal subjects
- Indirect mechanism. Saturates above 75mg/day, conversion efficiency varies
- PT-707
- Synthetic kisspeptin agonist
- 90 min SC
- Chronic-dosing HPG studies
- Improved pharmacokinetics vs kisspeptin-10 but limited human data. Phase 2 stage